
AI's $500 Billion Opportunity Begins With Reimagining Procurement
getty
We hear it all the time: AI is changing the way we work. Its capabilities are accelerating, transforming roles, redefining career paths and opening new avenues for growth and innovation. McKinsey and others argue that there is up to $500 billion in inefficiency trapped in procurement processes that are waiting to be transformed by automation and AI.
But what now? And where do you get started? Let me make a case for why AI should start with how buyers and sellers interact with one another to purchase goods and services in a more autonomous way.
This isn't just about digitizing or automating a business process. It's about transforming how you better source business relationships for materials, goods and services; redefining your teams' roles, decision-making speed and scale in the process; and revolutionizing business outcomes. When you change how work gets done and how things are procured, you can reshape your P&L—transforming it from a backward-looking ledger into a forward-looking growth engine.
Nowhere is this opportunity more apparent than in the world of procurement and spend management. Companies that embrace advanced AI technologies, such as agentic AI and GenAI, will widen the gap between themselves and their competitors. The ones that hesitate will struggle to play to win.
So, how do you start getting after this $500-billion opportunity?
Traditional procurement and cost management were reactive: tracking costs, managing risk, tackling strategic issues after the fact. We worked with fragmented data. We chased down invoices. We waited weeks to detect and respond to supply chain disruptions. We spent valuable time playing catch-up.
Data is the new flywheel.
AI flips that old model on its head. Today, speed and time are the new currency, with data serving as a flywheel effect. In a volatile economy, whoever can respond the fastest with the best data and intelligence wins.
In spend management, better data means smarter sourcing decisions, improved cash flow management, faster supplier collaboration and greater resilience across the board.
When you look at Gartner's recent CEO survey, 82% of companies expect productivity increases of 5% or more directly tied to AI. But that is just the tip of the iceberg. Efficiency gains of 10-50% are quickly becoming the new norm.
The message is clear: Good data is no longer a nice-to-have. It is a survival skill.
Recently, we hosted our annual customer conference in Las Vegas with over 2,000 of our enterprise customers and partners, and I was shocked by the number of customers that were actively operationalizing AI strategies across our platform or getting started on how to do so.
At this stage, merely experimenting with AI is not enough. Operationalizing AI—embedding it into the core of your enterprise management processes—is what will separate the leaders from everyone else.
The businesses that will thrive in the new normal are the ones where AI is actively driving their sourcing and purchasing decisions, optimizing things like supplier selection and payment timings, proactively identifying potential supplier or compliance risks and freeing up teams from manual tasks to perform higher-order, strategic work that generates revenue as opposed to merely cost-savings.
This is the new reality for CEOs and finance and procurement leaders, including chief supply chain officers. They are responsible now for this AI transformation, shaping how their businesses respond to disruption and capitalize on opportunity. They're no longer managing just the bottom line—they're helping redefine how we all work.
And this is not just theory. AI is taking the administrative burden off 'back office' teams so they can be repurposed and reimagined to perform more front office work. Take, for example, the case of a global bank, where they used AI to empower their former accounts payable team, refashioning their work to serve as customer renewal support teams and enabling them to earn 15% more in wages in the process. This is the true opportunity of today's leading AI platforms: to transform work, people and teams in this way.
They and other leading companies have taken manual tasks like invoice processing, fraud detection and payment reconciliation and fully automated them—giving their own people more time and space to focus on more impactful work.
AI is not just about eliminating jobs. It's about elevating them. It's about giving smart, capable people the best tools to do their best work—faster, with greater data and insight and with more purpose.
There is a common misconception that AI success is just about volume: Collect more data, feed it into models and wait for the magic to happen. The reality is different and far more demanding.
Getting the best data is what matters—data that is unified, trustworthy and purpose-built for the specific challenges you need to solve.
When it comes to spend management, that means ensuring that the platform you choose is built on ethically sourced, normalized and intelligently organized data from actual customer interactions. Without that 'real data' foundation, no amount of AI power will deliver meaningful results by simply scraping the internet.
Leaders need to ask themselves hard questions when it comes to the data feeding their AI strategies:
• What is the quality and source of our data behind this AI?
• How is it protected and governed?
• What outcomes has it proven in real business terms, and what is it telling us?
Speed without trust is reckless. Trust without speed is irrelevant. The reality is, you need both.
Many companies fall into the trap of assuming that any technology with an "AI-powered" label will meet their needs.
But there is a real difference between AI-native platforms—those built natively from the cloud, ground up to embed intelligence and orchestration at every layer—and legacy systems that bolt on AI capabilities after the fact, or AI that's built on nonstructured, unified data. AI models trained on fragmented data sets can miss key context and correlations, leading to slower AI model development, with inconsistent governance and quality control.
An AI-native platform learns and scales faster and adapts automatically as your business needs change. It treats AI not as an add-on but as the engine riding shotgun with your business, enabling real-time, holistic insights that drive better cross-functional outcomes.
In high-stakes areas like cost and spend management, where trillions in working capital, supplier relationships and operational resilience are on the line, this difference is not academic. It is critical.
Scrutinize your technology platforms. Ask yourself whether AI is embedded throughout the platform and is not just a new feature layered on top. Future-proofing your operations means investing in systems built for AI, speed, intelligence and trust from the start.
AI will be a game changer—not just for who survives, but for who leads. And in a world where the best data moat wins, the smartest investment is in systems and teams that can leverage this data to move fast, act strategically and create lasting enterprise value.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
China welcomes 183 Brazil coffee sellers in wake of US tariffs
By Ana Mano SAO PAULO (Reuters) -China has approved 183 new Brazilian coffee companies to export products to the Chinese market, according to a social media post of the Chinese embassy in Brazil on Saturday. The measure, a boon to local exporters after the United States government's announcement of steep tariffs on Brazilian coffee and other products, took effect on July 30. The new Chinese export permits are valid for five years, according to the post. The U.S.'s 50% tariff on some Brazilian products will begin on August 6. The levy represents a challenge for commodities traders and Brazilian coffee exporters, who need to find alternatives for the roughly 8 million bags sold to U.S. coffee processors every year. China is Brazil's top trade partner overall while the U.S. is a big buyer of Brazilian beef and orange juice, among other products. In June, Brazilian coffee exports into the U.S. totaled 440,034 60-kilo bags, 7,87 times more than Brazil's sales into China of nearly 56,000 bags that month, according to trade data compiled by industry lobby Cecafe. The Brazilian ministry of agriculture and Cecafe did not have an immediate comment. China's customs authority could not be immediately reached as it was outside the business hours. Brazil supplies about a third of the U.S. coffee demand each year, a trade valued at $4.4 billion in the 12 months ended in June. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Ball (NYSE:BALL) Will Pay A Dividend Of $0.20
The board of Ball Corporation (NYSE:BALL) has announced that it will pay a dividend of $0.20 per share on the 16th of September. Including this payment, the dividend yield on the stock will be 1.4%, which is a modest boost for shareholders' returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Ball's Projected Earnings Seem Likely To Cover Future Distributions The dividend yield is a little bit low, but sustainability of the payments is also an important part of evaluating an income stock. Prior to this announcement, Ball was quite comfortably covering its dividend with earnings and it was paying more than 75% of its free cash flow to shareholders. The company is clearly earning enough to pay this type of dividend, but it is definitely focused on returning cash to shareholders, rather than growing the business. Looking forward, earnings per share is forecast to rise by 135.1% over the next year. Assuming the dividend continues along recent trends, we think the payout ratio could be 20% by next year, which is in a pretty sustainable range. Check out our latest analysis for Ball Ball Has A Solid Track Record Even over a long history of paying dividends, the company's distributions have been remarkably stable. The annual payment during the last 10 years was $0.26 in 2015, and the most recent fiscal year payment was $0.80. This means that it has been growing its distributions at 12% per annum over that time. We can see that payments have shown some very nice upward momentum without faltering, which provides some reassurance that future payments will also be reliable. Ball Could Grow Its Dividend Investors could be attracted to the stock based on the quality of its payment history. Ball has seen EPS rising for the last five years, at 5.8% per annum. Shareholders are getting plenty of the earnings returned to them, which combined with strong growth makes this quite appealing. Our Thoughts On Ball's Dividend Overall, it's nice to see a consistent dividend payment, but we think that longer term, the current level of payment might be unsustainable. While Ball is earning enough to cover the dividend, we are generally unimpressed with its future prospects. We would be a touch cautious of relying on this stock primarily for the dividend income. It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. Case in point: We've spotted 2 warning signs for Ball (of which 1 shouldn't be ignored!) you should know about. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 9 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 65% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals. Check out our latest analysis for Rigel Pharmaceuticals What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Rigel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Rigel Pharmaceuticals' earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 15% of Rigel Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that BlackRock, Inc. is the largest shareholder with 9.7% of shares outstanding. Armistice Capital LLC is the second largest shareholder owning 8.5% of common stock, and Morgan Stanley, Investment Banking and Brokerage Investments holds about 8.3% of the company stock. Furthermore, CEO Raul Rodriguez is the owner of 0.8% of the company's shares. We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Rigel Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Rigel Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$5.5m worth of the US$392m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. General Public Ownership With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Rigel Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 1 warning sign for Rigel Pharmaceuticals that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data